The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.